roche_scientists

Which are pharma’s most innovative companies?

December 11, 2015
Medical Communications, Research and Development GSK, Roche, research and development

It has been a record-breaking year for the pharmaceutical industry in terms of deals, but what about the underlying innovation …

AZ_scientist

AstraZeneca deal to delve into the secretome

December 11, 2015
Medical Communications, Research and Development AstraZeneca, MedImmune, biologics, secretome

MedImmune, the biologics research and development arm of pharma giant AstraZeneca, has signed a collaboration with Swedish universities and research …

NICE publishes draft guidance on two prostate cancer treatments

December 11, 2015
Medical Communications, Research and Development, Sales and Marketing Astellas, Janssen, NICE, Xtandi, Zytiga, prostate cancer

NICE has issued final draft guidance recommending Astellas Pharma’s Xtandi (enzalutamide) in prostate cancer prior to chemotherapy, but not Janssen’s …

xarelto

Regulators to probe Bayer’s Xarelto trial results

December 10, 2015
Medical Communications, Research and Development

Bayer’s blockbuster anticoagulant Xarelto is under scrutiny from regulators in Europe and the US, as they try to determine whether …

Novolog pen

Novo Nordisk files for new insulin approval

December 10, 2015
Manufacturing and Production, Research and Development, Sales and Marketing FDA, NDA, Novo Nordisk, NovoLog, diabetes, insulin aspart, new drug application

Novo Nordisk has submitted a New Drug Application (NDA) for faster-acting insulin aspart to the FDA. If successful, the Danish …

Merck researcher

Merck/Pfizer Alliance to collaborate on late-stage cancer trials

December 10, 2015
Research and Development Merck, Pfizer, avelumab, collaboration, gastric cancer, oncology, partnership, stomach cancer

Merck and Pfizer are partnering to run two Phase III trials of avelumab, an immuno-oncology treatment the companies hope to …

cindy_whitehead

‘Female Viagra’ CEO leaves company

December 10, 2015
Medical Communications, Sales and Marketing Addyi, Cindy Whitehead, Sprout Pharma

Cindy Whitehead has left Sprout Pharmaceuticals, just four months after guiding the female libido drug Addyi to FDA approval and overseeing …

Guido Rasi

EMA sets out new five-year plan

December 9, 2015
Research and Development EMA, Guido Rasi

The European Medicines Agency’s (EMA) new executive director, Professor Guido Rasi, outlined his vision for his five-year mandate at the …

MHRA

Early UK access for AstraZeneca lung cancer drug

December 9, 2015
AstraZeneca, Early Access to Medicines Scheme, Tagrissa, eams, lung cancer, non small cell lung cancer, non-small cell lung cancer, osimertinib

UK patients will be among the first in Europe to have free access to AstraZeneca’s cancer drug osimertinib, after the …

Janssen image

Janssen submits Stelara for EU approval for Crohn’s

December 9, 2015
Sales and Marketing Crohn’s disease, EMA, European Medicines Agency, Janssen, Stelara, crohn's disease, ustekinumab

Janssen today announced that it has submitted an application to the European Medicines Agency, seeking approval of Stelara in Crohn’s …

mackayjimeson_1345198498_140

Two new corporate affairs leads appointed at Pfizer

December 9, 2015
Medical Communications Pfizer, corporate affairs

Pfizer has appointed MacKay Jimeson and Niesha Foster as corporate affairs leads. The company recently restructured its global pharma business …

sign-web

Daiichi Sankyo rocked by further job losses

December 9, 2015
Manufacturing and Production Daiichi, Daiichi Sankyo

The Japanese pharma firm Daiichi Sankyo is to close an antibody-producing subsidiary in Germany, as the company continues to cut …

roche_claudia

New member appointed to Roche board of directors

December 9, 2015
Business Services Roche

The Roche board of directors has proposed Dr Claudia Süssmuth Dyckerhoff, currently senior partner at McKinsey & Company, for election …

mark_forbes_irving

Former Quintiles director joins IDEA Pharma as MD

December 9, 2015
Medical Communications, Sales and Marketing IDEA Pharma, Mark Forbes Irving

IDEA Pharma has appointed Mark Forbes Irving as managing director. With over 20 years’ industry experience, the new managing director joins …

healthy-human-t-cell_credit_celgene-web

Researchers launch CAR-T cell therapy trial in head and neck cancer

December 9, 2015
Research and Development CAR-T, CAR-T therapy, Cancer, head and neck cancers, oncology R&D

A pioneering trial is beginning in London, where doctors are harnessing patients’ own immune systems to find a new effective …

Coartem dosing

Novartis reaches 300 million free antimalarial treatments

December 9, 2015
Manufacturing and Production, Research and Development Coartem, Novartis, antimalarial treatment, malaria, non-profit

Novartis has reached a delivery milestone of 300 million paediatric antimalarial treatments, having supplied its Coartem dispersible without profit to …

Collaboration

The age of collaboration: why pharma companies now have to work together

December 9, 2015
Research and Development R&D, co-operation, collaboration, pharma

It seems 2015 may be remembered as the year of the mega merger; the year when all records were broken …

Scotland flag

Cancer and MS drugs approved in Scotland

December 9, 2015
Sales and Marketing Celgene, Copaxone, Novartis, SMC, Scottish Medicines Consortium, Tevaq, ceritinib, glatiramer acetate, lenalidomide, lung cancer, multiple myeloma, multiple sclerosis, revlimis, zykadia

The Scottish Medicines Consortium (SMC) has approved three new treatments for lung cancer, multiple sclerosis and multiple myeloma, from Novartis, …

Gilead sign

Gilead awaits EU decision on hep C combo treatment

December 8, 2015
Research and Development EMA, Gilead, SOF/VEL, accelerated assessment, hepatitis C, sovaldi, velpatasvir

The EMA has granted Gilead Sciences an accelerated assessment for its application for a new Sovaldi combination treatment.The combination contains …

Red blood cells

ASH 2015 roundup: Amgen, MorphoSys, Novartis and Roche present new trial data

December 8, 2015
Research and Development Amgen, Cancer, Novartis, Roche, ash, morphosys, oncology

Amgen Amgen presented data from three Phase II trials evaluating Blincyto (blinatumomab) in acute lymphoblastic leukemia (ALL)- a rare and …

The Gateway to Local Adoption Series

Latest content